AMRN Amarin

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.
Company profile
Ticker
AMRN
Exchange
Website
CEO
John Thero
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AMARIN PHARMACEUTICALS PLC, ETHICAL HOLDINGS PLC
SEC CIK
Corporate docs
AMRN stock data
()
News
Cramer Weighs In On Paysafe, Xilinx And More
15 Apr 21
TENX: HELP Results & New Asset to Boot
14 Apr 21
50 Biggest Movers From Yesterday
14 Apr 21
12 Health Care Stocks Moving In Tuesday's Intraday Session
13 Apr 21
The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug
13 Apr 21
Press releases
VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in New Analyses of EVAPORATE Study Presented as Late-Breaking Science at ESC Preventive Cardiology 2021
17 Apr 21
Amarin Announces CEO Succession Plan
12 Apr 21
Amarin Commences Commercial Initiatives for VAZKEPA in European Union Following Recent Regulatory Approval for Cardiovascular Risk Reduction Indication
6 Apr 21
Amarin Receives European Commission (EC) Approval for VAZKEPA to Reduce Cardiovascular Risk
30 Mar 21
HLS Therapeutics Announces that Icosapent Ethyl (Vascepa®) is Included in the 2021 Canadian Cardiovascular Society (CCS) Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults
29 Mar 21
Investment data
Securities sold
Number of investors
Calendar
25 Feb 21
17 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from Amarin earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 186.96M | 186.96M | 186.96M | 186.96M | 186.96M | 186.96M |
Cash burn (monthly) | 6.75M | 38.14M | (positive/no burn) | 1.58M | 12.77M | 1.81M |
Cash used (since last report) | 24.12M | 136.3M | n/a | 5.65M | 45.66M | 6.48M |
Cash remaining | 162.85M | 50.67M | n/a | 181.32M | 141.31M | 180.49M |
Runway (months of cash) | 24.1 | 1.3 | n/a | 114.8 | 11.1 | 99.6 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Mar 21 | Joseph T Kennedy | Ordinary Shares | Payment of exercise | Dispose F | No | No | 6.37 | 3,803 | 24.23K | 304,192 |
31 Mar 21 | Joseph T Kennedy | Ordinary Shares | Option exercise | Aquire M | No | No | 0 | 3,610 | 0 | 307,995 |
31 Mar 21 | Joseph T Kennedy | Ordinary Shares | Option exercise | Aquire M | No | No | 0 | 1,805 | 0 | 304,385 |
31 Mar 21 | Joseph T Kennedy | Ordinary Shares | Option exercise | Aquire M | No | No | 0 | 1,805 | 0 | 302,580 |
31 Mar 21 | Joseph T Kennedy | RSU Ordinary Shares | Option exercise | Dispose M | No | No | 0 | 3,610 | 0 | 18,050 |
31 Mar 21 | Joseph T Kennedy | RSU Ordinary Shares | Option exercise | Dispose M | No | No | 0 | 1,805 | 0 | 9,025 |
31 Mar 21 | Joseph T Kennedy | RSU Ordinary Shares | Option exercise | Dispose M | No | No | 0 | 1,805 | 0 | 9,025 |
31 Mar 21 | Steven B Ketchum | Ordinary Shares | Payment of exercise | Dispose F | No | No | 6.37 | 3,128 | 19.93K | 440,230 |
31 Mar 21 | Steven B Ketchum | Ordinary Shares | Option exercise | Aquire M | No | No | 0 | 3,056 | 0 | 443,358 |
31 Mar 21 | Steven B Ketchum | Ordinary Shares | Option exercise | Aquire M | No | No | 0 | 1,528 | 0 | 440,302 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
37.7% owned by funds/institutions
13F holders |
Current |
---|---|
Total holders | 242 |
Opened positions | 43 |
Closed positions | 60 |
Increased positions | 42 |
Reduced positions | 86 |
13F shares |
Current |
---|---|
Total value | 1.08B |
Total shares | 148.39M |
Total puts | 5.7M |
Total calls | 7.21M |
Total put/call ratio | 0.8 |
Largest owners |
Shares | Value |
---|---|---|
Baker Bros. Advisors | 27.99M | $136.88M |
Eversept Partners | 15.94M | $77.97M |
BVF | 10.76M | $52.62M |
Boxer Capital | 6M | $29.34M |
Avoro Capital Advisors | 6M | $29.34M |
MS Morgan Stanley | 5.98M | $29.22M |
Grosvenor Holdings, L.L.C. | 5.89M | $28.8M |
SCP Investment | 5.5M | $26.9M |
Clearbridge Advisors | 4.63M | $22.62M |
Rock Springs Capital Management | 4.2M | $20.51M |
Financial report summary
?Competition
Ionis Pharmaceuticals • Astrazeneca • Novartis • Intercept Pharmaceuticals • Acasti Pharma • Cardax • Abbvie • Matinas Biopharma • NeuroBo PharmaceuticalsContent analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
affiliate, ahead, Aid, AMPLIFY, angiographic, answer, Arabia, argued, attitude, Bahrain, beneficiary, Benjamin, Biden, biosimilar, boxed, Brigham, burdensome, CABG, CADTH, CAL, calcium, capita, career, CD, certiorari, checking, CHMP, CID, clear, cohesively, commenrcialization, composed, consequentially, contact, contacting, convince, coordinated, coordination, DEF, Defintiion, dense, destabilized, DH, diagnosed, diligently, discouraged, distancing, distracting, divergence, doctor, DOJ, drop, dying, EC, economy, Edding, elderly, emia, emphasize, emphasizing, ensued, era, excellence, Fake, fewer, fibrofatty, forthcoming, Franc, FY, FYs, gated, gender, geographically, globe, Grafenauweg, grafting, hall, hard, Harvard, height, heightened, hereinafter, hereto, honor, honoring, hope, hourly, hypercholesterol, IA, IIb, impeding, inexpensive, infected, infection, inflow, influenza, Inilne, input, Inspector, intelligence, Irelnad, irrespective, ischemic, Italy, Justice, justified, Lable, LAP, lenient, leverage, Liaison, Linkbase, LYPDISO, manmade, MDCT, medium, metformin, MFN, modest, morale, multidetector, multifactorial, multivariable, NMPA, Nordic, OIG, OMEMI, OPML, optimistic, orientation, overly, overturned, pandemic, paused, PCI, PD, Peterson, postulated, precautionary, predominately, prostate, race, reaccelerate, reactive, receent, rehearin, reinforcement, reinstitution, religion, remote, remotely, renumeration, reportedly, reprioritization, respitory, restraining, resume, resumed, resumption, retention, rewarding, rightsized, Saudi, saving, scan, Schema, School, score, Secretary, sequester, sexual, SHTG, signature, singly, slightly, speaker, speaking, spike, steadily, strained, summer, surgical, surrendered, Switzerland, symptom, symptomatic, talent, Taxanomy, Taxonmy, TCT, tension, text, timeframe, tissue, tolderated, tomography, town, traditional, Transcatheter, treble, TRIAGE, undergone, underwent, unrealized, unscheduled, upholding, uptake, usage, vaccinated, VASEPA, vast, VAZKEPA, viral, widespread, witnessed, workforce, worsened, worsensed, worst, writ, wrong, Zug
Removed:
abandon, abnormally, Acasti, acceleration, aggressively, amounted, attractive, BCF, bifurcation, bond, bridge, cancelled, CaPre, classification, concomitantly, contingency, conversion, Covenant, dedicate, Deed, default, dismissal, Docket, domain, encumber, entirety, existed, expensing, feasibility, formed, generation, host, house, inclusive, initiating, injunctive, instituted, issuable, krill, largely, leased, mandatorily, marked, maturing, Medica, membrane, memorandum, morbidity, Neptune, Nisshin, notified, notifying, partnering, perfected, pertaining, plasticity, prefer, prepay, preserving, pretrial, privately, provisional, PTAB, ran, recalculated, reclassification, reclassified, refinement, remedy, representation, rescinding, restate, send, shortfall, speculative, subscribed, Subtopic, Tariff, training, transition, unchanged, uncured, USITC, vulnerability, warrant, wholly
Financial reports
10-K
2020 FY
Annual report
25 Feb 21
10-Q
2020 Q3
Quarterly report
5 Nov 20
10-Q
2020 Q2
Quarterly report
4 Aug 20
10-Q
2020 Q1
Quarterly report
30 Apr 20
10-K/A
2019 FY
Annual report (amended)
29 Apr 20
10-K
2019 FY
Annual report
25 Feb 20
10-Q
2019 Q3
Quarterly report
5 Nov 19
10-Q
2019 Q2
Quarterly report
31 Jul 19
10-Q
2019 Q1
Quarterly report
1 May 19
10-K
2018 FY
Annual report
27 Feb 19
Current reports
8-K
Amarin Announces CEO Succession Plan
12 Apr 21
8-K
Amarin Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
25 Feb 21
8-K
Departure of Directors or Certain Officers
29 Jan 21
8-K
Amarin Provides Preliminary 2020 Results and 2021 Outlook
7 Jan 21
8-K
Amarin Reports Third Quarter 2020 Financial Results and Provides Business Update
5 Nov 20
8-K
Amarin Provides Update Following Ruling in VASCEPA® ANDA Patent Litigation
3 Sep 20
8-K
Amarin Reports Second Quarter 2020 Financial Results and Provides Update on Operations
4 Aug 20
8-K
Departure of Directors or Certain Officers
14 Jul 20
8-K
Other Events
16 Jun 20
8-K
Other Events
8 May 20
Registration and prospectus
S-8
Registration of securities for employees
4 Aug 20
S-3ASR
Automatic shelf registration
26 Feb 20
424B5
Prospectus supplement for primary offering
19 Jul 19
424B5
Prospectus supplement for primary offering
17 Jul 19
F-6EF
Automatic registration for ADRs (foreign)
29 Nov 18
424B5
Prospectus supplement for primary offering
28 Nov 18
424B5
Prospectus supplement for primary offering
26 Nov 18
424B5
Prospectus supplement for primary offering
30 Jan 18
424B5
Prospectus supplement for primary offering
28 Jan 18
S-8
Registration of securities for employees
1 Aug 17
Proxies
DEF 14A
Definitive proxy
1 Jun 20
DEF 14A
Definitive proxy
25 Apr 19
PRE 14A
Preliminary proxy
15 Apr 19
DEF 14A
Definitive proxy
19 Apr 18
DEF 14A
Definitive proxy
20 Apr 17
DEF 14A
Definitive proxy
28 Apr 16
DEF 14A
Definitive proxy
23 Apr 15
PRE 14A
Preliminary proxy
2 Apr 15
DEF 14A
Definitive proxy
29 Apr 14
DEF 14A
Definitive proxy
22 Apr 13
Other
CT ORDER
Confidential treatment order
4 Apr 18
CT ORDER
Confidential treatment order
21 Sep 17
UPLOAD
Letter from SEC
16 Jan 17
CORRESP
Correspondence with SEC
8 Jan 17
UPLOAD
Letter from SEC
26 Dec 16
EFFECT
Notice of effectiveness
6 Aug 15
CORRESP
Correspondence with SEC
4 Aug 15
UPLOAD
Letter from SEC
2 Aug 15
CT ORDER
Confidential treatment order
30 Jun 15
EFFECT
Notice of effectiveness
30 Apr 15
Ownership
4
AMARIN / Aaron Berg ownership change
2 Apr 21
4
AMARIN / Michael Wayne Kalb ownership change
2 Apr 21
4
AMARIN / Steven B Ketchum ownership change
2 Apr 21
4
AMARIN / Joseph T Kennedy ownership change
2 Apr 21
4
AMARIN / JOHN F THERO ownership change
2 Apr 21
4
AMARIN / Aaron Berg ownership change
1 Mar 21
4
AMARIN / Michael Wayne Kalb ownership change
1 Mar 21
4
AMARIN / Steven B Ketchum ownership change
1 Mar 21
4
AMARIN / Joseph T Kennedy ownership change
1 Mar 21
4
AMARIN / JOHN F THERO ownership change
1 Mar 21
Patents
GRANT
Utility
Compositions and methods for lowering levels of high-sensitivity C-reactive protein (hs-CRP) in a subject
13 Apr 21
The present disclosure provides methods for treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
GRANT
Utility
Methods of reducing apolipoprotein c-III
13 Apr 21
In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
APP
Utility
Methods of Treating Mixed Dyslipidemia
8 Apr 21
The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.
APP
Utility
Methods of Treating Mixed Dyslipidemia
8 Apr 21
The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.
APP
Utility
Methods of Reducing the Risk of Cardiovascular Events In a Subject
8 Apr 21
In various embodiments, the present disclosure provides methods reducing the risk of cardiovascular events in a subject on statin therapy by administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.
Transcripts
2020 Q4
Earnings call transcript
25 Feb 21
2020 Q3
Earnings call transcript
5 Nov 20
2020 Q2
Earnings call transcript
4 Aug 20
2020 Q1
Earnings call transcript
30 Apr 20
2020 Q1
Earnings call transcript
13 Apr 20
2019 Q4
Earnings call transcript
25 Feb 20
2019 Q3
Earnings call transcript
5 Nov 19
2019 Q2
Earnings call transcript
1 Aug 19
2019 Q1
Earnings call transcript
1 May 19
2018 Q4
Earnings call transcript
27 Feb 19
Reddit threads
r/Stocks Daily Discussion Wednesday - Apr 14, 2021
14 Apr 21
Stocks that will benefit from Obesity Related Illness?
13 Apr 21
What has been your best trade and worst trade?
11 Apr 21
AMRN buyout soon FORM4's "In the case of a Change of Control" not in prior Form 4's
5 Apr 21
AMRN buyout soon FORM4's "In the case of a Change of Control" not in prior Form 4's
5 Apr 21
AMRN room to grow
4 Apr 21
Upcoming AMRN news that will shoot it to the moon
4 Apr 21
AMRN news that will shoot it to the moon why?
4 Apr 21
$1,500 loss in 30 seconds day trading
4 Apr 21
AMRN news that may shoot it up like MRNA
3 Apr 21